Form 4: Alignment Healthcare CEO John Kao Sells 90,000 Shares Under Pre-Arranged Trading Plan

Alignment Healthcare, Inc. CEO John E. Kao has sold 90,000 shares of common stock for approximately $1.37 million, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (ALHC), disposed of 90,000 shares of the company's common stock.
• The transaction occurred on June 11, 2025, and was executed under a Rule 10b5-1 trading plan adopted on March 14, 2024.
• The shares were sold at a weighted-average price of $15.2689 per share, with individual transaction prices ranging from $14.61 to $15.58.
• Following this transaction, Mr. Kao directly beneficially owns 4,923,186 shares of common stock.
• Additionally, Mr. Kao indirectly beneficially owns 1,823,100 shares through the JEK Trust, dated February 8, 2021, for which he serves as trustee.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant insider sale by the CEO, which can sometimes be perceived as a lack of confidence. However, the negative impact is mitigated by the fact that the sale was pre-planned under a Rule 10b5-1 plan, indicating it was not based on new, undisclosed negative information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, which indicates the transaction was pre-scheduled and not based on immediate, non-public information, potentially mitigating concerns about opportunistic insider selling.

Negatives

• A significant sale of 90,000 shares by the Chief Executive Officer, even if pre-planned, can sometimes be perceived by the market as a reduction in management's direct equity exposure and conviction in the company's near-term prospects.
• The sale reduces the CEO's direct ownership stake in the company, although a substantial number of shares are still held directly and indirectly.

Risks

• Potential negative market sentiment or investor interpretation regarding the CEO's stock sale, despite it being part of a 10b5-1 plan.
• The reduction in direct insider ownership could be viewed as a slight decrease in alignment between management and shareholder interests, depending on the overall context of the CEO's compensation and holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is specific to an insider transaction at Alignment Healthcare, Inc. and does not provide broader industry context or trends. Insider sales are a common occurrence across various industries, often for personal financial planning reasons, especially when executed under a Rule 10b5-1 plan.

Corporate Governance

Related Party Transactions

• John E. Kao indirectly holds 1,823,100 shares of common stock through the JEK Trust, dated February 8, 2021, of which he is the trustee. This represents a related party holding.

Stakeholder Impact

• Shareholders: May interpret the CEO's sale as a signal, potentially leading to short-term price fluctuations, although the 10b5-1 plan context should temper significant negative reactions.
• Employees: No direct impact mentioned, but general market perception could indirectly affect morale or confidence.

Key Dates

Recommendation

Keywords

Alignment Healthcare, ALHC, John E. Kao, CEO, Director, Stock Sale, Insider Transaction, Form 4, 10b5-1 Plan, Equity Disposal, Healthcare, Managed Care